• Mr. Samaksh Tyagi
• Dr. Rakesh Das

In pandemic period of COVID-19, apart from age, immunodeficiency, and invaded super infection conditions some other co-morbid conditions are becoming footprint of increase mortality rate and invitation to mutant COVID genome viability. Findings are to be specially contribute towards the evaluation of laid co-morbid condition which drag down the patient's community population onto dense of a critical situation. This critical condition of health will initiate the development-specific antiviral associated with antibiotic regime formulation. The methodology buds from investigation of data analysis of based on online collection of case studies and interpretation to get the core causes on a point where the health care is becoming a challenge for the investigation of specified drugs and formulation. COVID-19 is a burning investigatory topic where exact center-point of co-morbid categories could be evaluated in pandemic situation. And invention of specific medication tools to specify the remedial measures could be develop on behave of critical case as per the co-morbid categories in order to decline sharply the epidemic condition of COVID in population. On collecting COVID-19 information’s from various countries and various resources, hence opens no exclusion criteria’s on observation studies. It was observed that patient’s condition before taking medicines and after medicines are showing complex situations as health concern in different ways in COVID-19 patients. Thus, the treatment with antiviral drugs was not satisfactory for COVID-19. Therefore, vaccines are the alternative as acquired immunity support.

COVID-19, Antivirals, Comorbid condition, Data- Analysis, Effectivness.

"ANTIVIRAL DRUGS EVALUATION ON COVID-19 PATIENTS UNDER SPECIFIED CO-MORBID CONDITION: DATA ANALYSIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 6, page no.c469-c492, June-2021, Available :http://www.jetir.org/papers/JETIR2106337.pdf

"ANTIVIRAL DRUGS EVALUATION ON COVID-19 PATIENTS UNDER SPECIFIED CO-MORBID CONDITION: DATA ANALYSIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 6, page no. ppc469-c492, June-2021, Available at : http://www.jetir.org/papers/JETIR2106337.pdf